1. Home
  2. VCEL vs BPYPO Comparison

VCEL vs BPYPO Comparison

Compare VCEL & BPYPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VCEL
  • BPYPO
  • Stock Information
  • Founded
  • VCEL 1989
  • BPYPO N/A
  • Country
  • VCEL United States
  • BPYPO Bermuda
  • Employees
  • VCEL N/A
  • BPYPO 30200
  • Industry
  • VCEL Biotechnology: Biological Products (No Diagnostic Substances)
  • BPYPO Real Estate
  • Sector
  • VCEL Health Care
  • BPYPO Finance
  • Exchange
  • VCEL Nasdaq
  • BPYPO Nasdaq
  • Market Cap
  • VCEL 2.1B
  • BPYPO N/A
  • IPO Year
  • VCEL 1997
  • BPYPO N/A
  • Fundamental
  • Price
  • VCEL $40.15
  • BPYPO $15.25
  • Analyst Decision
  • VCEL Strong Buy
  • BPYPO
  • Analyst Count
  • VCEL 8
  • BPYPO 0
  • Target Price
  • VCEL $62.00
  • BPYPO N/A
  • AVG Volume (30 Days)
  • VCEL 430.8K
  • BPYPO N/A
  • Earning Date
  • VCEL 07-31-2025
  • BPYPO N/A
  • Dividend Yield
  • VCEL N/A
  • BPYPO N/A
  • EPS Growth
  • VCEL 521.85
  • BPYPO N/A
  • EPS
  • VCEL 0.05
  • BPYPO N/A
  • Revenue
  • VCEL $238,541,000.00
  • BPYPO N/A
  • Revenue This Year
  • VCEL $23.03
  • BPYPO N/A
  • Revenue Next Year
  • VCEL $24.52
  • BPYPO N/A
  • P/E Ratio
  • VCEL $705.61
  • BPYPO N/A
  • Revenue Growth
  • VCEL 14.80
  • BPYPO N/A
  • 52 Week Low
  • VCEL $37.39
  • BPYPO N/A
  • 52 Week High
  • VCEL $63.00
  • BPYPO N/A
  • Technical
  • Relative Strength Index (RSI)
  • VCEL 44.33
  • BPYPO 63.81
  • Support Level
  • VCEL $40.53
  • BPYPO $14.62
  • Resistance Level
  • VCEL $43.57
  • BPYPO $15.22
  • Average True Range (ATR)
  • VCEL 1.62
  • BPYPO 0.33
  • MACD
  • VCEL -0.16
  • BPYPO 0.05
  • Stochastic Oscillator
  • VCEL 28.65
  • BPYPO 87.40

About VCEL Vericel Corporation

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

About BPYPO Brookfield Property Partners L.P.

Brookfield Property Partners LP owns, operates, and invests in commercial properties in North America, Europe, Australia, and Brazil. The company focuses on being an owner and operator of real estate, providing investors with diversified exposure to some of the iconic properties and acquiring high-quality assets at a discount to replacement cost or intrinsic value. Its operating segment includes Core Office, Core Retail, LP Investments, and Corporate Segments. The company operates in various sectors such as the office sector, retail sector, industrial, multifamily, hospitality, triple net lease, and corporate sector. It generates a majority of revenue from the LP Investments segment.

Share on Social Networks: